Former President Donald Trump announced a major initiative aimed at slashing prescription drug costs, presenting it as both a triumph of economic policy and a fulfillment of a long-standing campaign promise. In partnership with pharmaceutical giant Pfizer, the plan allows Medicaid programs to purchase medications at prices comparable to those paid by other developed nations. Under the new “Most Favored Nation” (MFN) model, some prescription drugs could see price reductions of up to 80 percent, a move Trump described as a “historic correction” to decades of inflated pharmaceutical costs in the United States.

The policy, initially delayed by the pandemic, represents a centerpiece of Trump’s effort to make healthcare more affordable without compromising innovation. By linking U.S. drug prices to the lowest rates among international markets, the administration hopes to level the playing field and ensure Americans are no longer paying disproportionately high prices for the same medications. Health officials and economic advisers praised the decision as a long-overdue reform that could significantly reduce costs for patients, particularly seniors and low-income families who depend on Medicaid support.

The announcement also arrives at a politically strategic moment, as Trump’s approval rating has risen to 53 percent according to Rasmussen Reports—his highest in months. Supporters view the policy as proof of his ability to deliver tangible economic benefits, while critics question whether the pharmaceutical industry will resist through legal or logistical challenges.

Trump framed the initiative not only as an economic reform but as a moral and political victory, emphasizing fairness and global competitiveness. “Americans should never pay more for the same drug than people in other countries,” he said, positioning the policy as a cornerstone of his broader effort to protect consumers and restore balance in international trade and healthcare pricing.